Curiato, Inc.

This study is evaluating a clinical treatment regimen that involves two investigational drugs, Pozelimab and Cemdisiran, given in combination. The study population is people with paroxysmal nocturnal hemoglobinuria (PNH). The purpose of this study is to learn about the safety and effectiveness of the combination of Pozelimab and Cemdisiran in treating people with PNH and to compare it with 2 existing treatments, one called Ravulizumab and the other called Eculizumab. The combination of Pozelimab and Cemdisiran may be called the "study drug," and Ravulizumab and Eculizumab may be called the "control drugs." This study focuses on the following research questions: How effective is the combination of Pozelimab and Cemdisiran compared to Ravulizumab? How effective is the combination of Pozelimab and Cemdisiran compared to Eculizumab? What side effects may occur with the study drug? How much study drug is in your blood at different times? Will your body develop antibodies against the study drug (which may make the study drug less effective or cause side effects)